Menu
Search
|

Menu

Close
X

Immunomedics Inc IMMU.OQ (NASDAQ Stock Exchange Global Market)

19.43 USD
+0.52 (+2.75%)
As of 8:59 PM GMT
chart
Previous Close 18.91
Open 18.80
Volume 1,039,801
3m Avg Volume 552,493
Today’s High 19.69
Today’s Low 18.32
52 Week High 27.32
52 Week Low 8.68
Shares Outstanding (mil) 125.38
Market Capitalization (mil) 1,461.92
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
2
FY17
3
FY16
3
FY15
6
EPS (USD)
FY19
-0.343
FY18
-1.696
FY17
-1.437
FY16
-0.623
FY15
-0.514
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
472.92
5.69
Price to Book (MRQ)
vs sector
--
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
--
15.71
LT Debt to Equity (MRQ)
vs sector
--
11.53
Return on Investment (TTM)
vs sector
-367.82
15.05
Return on Equity (TTM)
vs sector
--
16.62

EXECUTIVE LEADERSHIP

Behzad Aghazadeh
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Michael Pehl
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Usama Malik
Interim Chief Financial Officer and Principal Financial Officer, Since 2018
Salary: --
Bonus: --
Morris Rosenberg
Chief Technology Officer, Since
Salary: --
Bonus: --
William Fricker
Principal Accounting Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

300 the American Rd
MORRIS PLAINS   NJ   07950-2460

Phone: +1973.6058200

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

SPONSORED STORIES